COVID-19 in Relation to Chronic Antihistamine Prescription
No hospitalizations or deaths occurred in residents with the COVID-19 infection, treated with antihistamines and azithromycin, of two external nursing homes during the first wave. We assessed whether patients receiving chronic antihistamines in our institution showed better clinical evolution. COVID...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/12/12/2589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846103477259862016 |
|---|---|
| author | Anna Puigdellívol-Sánchez Marta Juanes-González Ana Calderón-Valdiviezo Helena Losa-Puig Roger Valls-Foix Marta González-Salvador Celia Lozano-Paz Josep Vidal-Alaball |
| author_facet | Anna Puigdellívol-Sánchez Marta Juanes-González Ana Calderón-Valdiviezo Helena Losa-Puig Roger Valls-Foix Marta González-Salvador Celia Lozano-Paz Josep Vidal-Alaball |
| author_sort | Anna Puigdellívol-Sánchez |
| collection | DOAJ |
| description | No hospitalizations or deaths occurred in residents with the COVID-19 infection, treated with antihistamines and azithromycin, of two external nursing homes during the first wave. We assessed whether patients receiving chronic antihistamines in our institution showed better clinical evolution. COVID-19 admissions and related deaths in the public Hospital of Terrassa (<i>n</i> = 1461) during the pandemic period (11 March 2020–5 May 2023) and cases (<i>n</i> = 32,888) during the period of full suspicion diagnosis (1 June 2020–23 March 2022) were referred to as the number of chronic treatments (nT) including or not including antihistamines (AntiHm or NOAntiHm), and their vaccination status before the first infection (VAC or NoVAC) in our assigned population (<i>n</i> = 140,681 at March 2020) was recorded. No deaths occurred in patients treated with up to ≤6 nT in the AntiHm group in all ages. A significant reduction in hospital admission was observed in the 2–7 nT groups either below or over 60 years old [Odds Ratio (OR) NoAntiHm/AntiHm = 1.76–1.32, respectively, in NoVAC or VAC (OR = 2.10 overall] and in the older ≥8 nT group (OR = 2.08 in NoVac]. In conclusion, patients with chronic antihistamine prescriptions, alone or with polypharmacy, showed reduced hospital admission and mortality rates, suggesting the safety of antihistamine treatment and the need to confirm its effectiveness in a prospective trial. |
| format | Article |
| id | doaj-art-0661d9b1128f4f71b0b3bacb3518f41d |
| institution | Kabale University |
| issn | 2076-2607 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj-art-0661d9b1128f4f71b0b3bacb3518f41d2024-12-27T14:41:38ZengMDPI AGMicroorganisms2076-26072024-12-011212258910.3390/microorganisms12122589COVID-19 in Relation to Chronic Antihistamine PrescriptionAnna Puigdellívol-Sánchez0Marta Juanes-González1Ana Calderón-Valdiviezo2Helena Losa-Puig3Roger Valls-Foix4Marta González-Salvador5Celia Lozano-Paz6Josep Vidal-Alaball7Medicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainMedicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainMedicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainMedicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainMedicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainManagement, Control and Information Analysis Unit, Hospital de Terrassa, Consorci Sanitari de Terrassa (CST), Carretera de Torrebonica s/n, 08227 Terrassa, SpainMedicina de Familia, CAP Anton de Borja-Centre Universitari, c/Marconi-Cantonada Edison s/n, Consorci Sanitari de Terrassa (CST), 08191 Rubí, SpainIntelligence for Primary Care Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gurina, 08242 Manresa, SpainNo hospitalizations or deaths occurred in residents with the COVID-19 infection, treated with antihistamines and azithromycin, of two external nursing homes during the first wave. We assessed whether patients receiving chronic antihistamines in our institution showed better clinical evolution. COVID-19 admissions and related deaths in the public Hospital of Terrassa (<i>n</i> = 1461) during the pandemic period (11 March 2020–5 May 2023) and cases (<i>n</i> = 32,888) during the period of full suspicion diagnosis (1 June 2020–23 March 2022) were referred to as the number of chronic treatments (nT) including or not including antihistamines (AntiHm or NOAntiHm), and their vaccination status before the first infection (VAC or NoVAC) in our assigned population (<i>n</i> = 140,681 at March 2020) was recorded. No deaths occurred in patients treated with up to ≤6 nT in the AntiHm group in all ages. A significant reduction in hospital admission was observed in the 2–7 nT groups either below or over 60 years old [Odds Ratio (OR) NoAntiHm/AntiHm = 1.76–1.32, respectively, in NoVAC or VAC (OR = 2.10 overall] and in the older ≥8 nT group (OR = 2.08 in NoVac]. In conclusion, patients with chronic antihistamine prescriptions, alone or with polypharmacy, showed reduced hospital admission and mortality rates, suggesting the safety of antihistamine treatment and the need to confirm its effectiveness in a prospective trial.https://www.mdpi.com/2076-2607/12/12/2589COVID-19antihistamineshospital admissioninfection ratedeath ratepolypharmacy |
| spellingShingle | Anna Puigdellívol-Sánchez Marta Juanes-González Ana Calderón-Valdiviezo Helena Losa-Puig Roger Valls-Foix Marta González-Salvador Celia Lozano-Paz Josep Vidal-Alaball COVID-19 in Relation to Chronic Antihistamine Prescription Microorganisms COVID-19 antihistamines hospital admission infection rate death rate polypharmacy |
| title | COVID-19 in Relation to Chronic Antihistamine Prescription |
| title_full | COVID-19 in Relation to Chronic Antihistamine Prescription |
| title_fullStr | COVID-19 in Relation to Chronic Antihistamine Prescription |
| title_full_unstemmed | COVID-19 in Relation to Chronic Antihistamine Prescription |
| title_short | COVID-19 in Relation to Chronic Antihistamine Prescription |
| title_sort | covid 19 in relation to chronic antihistamine prescription |
| topic | COVID-19 antihistamines hospital admission infection rate death rate polypharmacy |
| url | https://www.mdpi.com/2076-2607/12/12/2589 |
| work_keys_str_mv | AT annapuigdellivolsanchez covid19inrelationtochronicantihistamineprescription AT martajuanesgonzalez covid19inrelationtochronicantihistamineprescription AT anacalderonvaldiviezo covid19inrelationtochronicantihistamineprescription AT helenalosapuig covid19inrelationtochronicantihistamineprescription AT rogervallsfoix covid19inrelationtochronicantihistamineprescription AT martagonzalezsalvador covid19inrelationtochronicantihistamineprescription AT celialozanopaz covid19inrelationtochronicantihistamineprescription AT josepvidalalaball covid19inrelationtochronicantihistamineprescription |